AstraZeneca has agreed a deal with drug maker Kyowa Hakko Kirin giving the UK pharmaceutical company the option to commercialise an asthma treatment in Japan.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca, Kyowa Hakko Kirin, research and development, benralizumab, licensing